These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7368144)

  • 21. [Thrombogenicity of prothrombin complex concentrates].
    Dornheim G; Klöcking HP; Wulkow R; Storch H; Töpfer G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):571-9. PubMed ID: 1714862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.
    Brinkman HJ; Patiwael S; Tripathi S; Meijers JC
    Thromb Res; 2016 Mar; 139():102-10. PubMed ID: 26916304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of plasma with high levels of ionised calcium in the production of model scale coagulation factor concentrates.
    Farrugia A; Douglas S; James J; Whyte G; Herrington R
    Thromb Haemost; 1990 Nov; 64(3):374-8. PubMed ID: 2128967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
    Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6.
    Kruithof EK; Mestries JC; Gascon MP; Ythier A
    Thromb Haemost; 1997 May; 77(5):905-10. PubMed ID: 9184401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro spontaneous thrombin generation in human factor-IX concentrates.
    Sas G; Owens RE; Smith JK; Middleton S; Cash JD
    Br J Haematol; 1975 Sep; 31(1):25-35. PubMed ID: 1212434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phospholipid composition of in vitro endothelial microparticles and their in vivo thrombogenic properties.
    Abid Hussein MN; Böing AN; Biró E; Hoek FJ; Vogel GM; Meuleman DG; Sturk A; Nieuwland R
    Thromb Res; 2008; 121(6):865-71. PubMed ID: 17889282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma.
    Duchemin J; Pan-Petesch B; Arnaud B; Blouch MT; Abgrall JF
    Thromb Haemost; 2008 Apr; 99(4):767-73. PubMed ID: 18392335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxicity of factor IX concentrates in mice.
    Magner A; Aronson D
    Dev Biol Stand; 1979; 44():185-8. PubMed ID: 544292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The fibrinolytic potential of the normal primate following the generation of thrombin in vivo.
    Giles AR; Nesheim ME; Herring SW; Hoogendoorn H; Stump DC; Heldebrant CM
    Thromb Haemost; 1990 Jun; 63(3):476-81. PubMed ID: 2402750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Various prothrombin complex concentrates and their effect on coagulation and fibrinolysis in vivo.
    Hedner U; Nilsson IM; Bergentz SE
    Thromb Haemost; 1976 Apr; 35(2):386-95. PubMed ID: 989639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bothrojaracin, a proexosite I ligand, inhibits factor Va-accelerated prothrombin activation.
    Monteiro RQ; Zingali RB
    Thromb Haemost; 2002 Feb; 87(2):288-93. PubMed ID: 11858489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
    Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
    Bohner J; von Pape KW; Blaurock M
    Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The activation of prothrombin complex concentrates by calcium in vitro.
    Exner T; Rickard KA
    Biomedicine; 1977 Mar; 27(2):62-5. PubMed ID: 861352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heparin-induced inhibitory effects of a prothrombin complex concentrate on global tests of haemostasis.
    Takeyama M; Sakurai Y; Shima M; Matsumoto T; Nogami K; Tanaka I; Takeda T; Giddings JC; Yoshioka A
    Blood Coagul Fibrinolysis; 2007 Jan; 18(1):1-7. PubMed ID: 17179819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma.
    Muntean W
    Wien Klin Wochenschr; 1984 Nov; 96(22):829-32. PubMed ID: 6442046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.